Loading
STMN1 (Stathmin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer.
Involved in the regulation of the microtubule (MT) filament system by destabilising microtubules. Prevents assembly and promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Paclitaxel.
In plain words · STMN1 (Stathmin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer.
STMN1 (Stathmin) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer.
Involved in the regulation of the microtubule (MT) filament system by destabilising microtubules. Prevents assembly and promotes disassembly of microtubules.
No product in this corpus aims at STMN1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA STMN1: RNA tissue enhanced (brain 1,367 nTPM, lymphoid tissue 1,250 nTPM); blood lineage group enriched (dendritic cells 425 nTPM, T-cells 144 nTPM); high antibody staining in 12 normal tissues; highest cancer staining testis cancer (9 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Endometrial cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas STMN1 tissue; Open Targets ENSG00000117632 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Zhu X.-X. et al, J. Biol. Chem, 1989, "Molecular cloning of a novel human leukemia-associated gene. Evidence of conservation in animal species". Source.
Sources: HGNC HGNC:6510 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P16949 (protein name, function text, keywords and locations (REST API)); CIViC gene STMN1 (1 evidence items, 0 assertions, 1 variants; diseases: Endometrial Carcinoma (GraphQL API, CC0))
Involved in the regulation of the microtubule (MT) filament system by destabilising microtubules. Prevents assembly and promotes disassembly of microtubules. Phosphorylation at Ser-16 may be required for axon formation during neurogenesis. Involved in the control of the learned and innate fear. Location: Cytoplasm, cytoskeleton (UniProt). Locus 1p36.11 (HGNC).
RNA: tissue enhanced (brain 1,367 nTPM, lymphoid tissue 1,250 nTPM), detected in all normal tissues. Blood: group enriched (dendritic cells 425 nTPM, T-cells 144 nTPM).
Medium: Appendix, Breast, Cerebellum, Cerebral cortex, Cervix, Esophagus, Hippocampus, Kidney.
Medium only: head and neck cancer, pancreatic cancer, urothelial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"STMN1" OR ABSTRACT:"STMN1" OR TITLE:"stathmin 1" OR ABSTRACT:"stathmin 1" OR TITLE:"Stathmin" OR ABSTRACT:"Stathmin" OR TITLE:"OP18" OR ABSTRACT:"OP18" OR TITLE:"PR22" OR ABSTRACT:"PR22" OR TITLE:"PP19" OR ABSTRACT:"PP19") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STMN1, not a curated reading list.